PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩65 per share · Prices as of the 2026-10-02 close
Dongwha Pharm saw full-year 2025 operating profit nearly disappear, but cost efficiency drove a sharp two-quarter operating profit rebound in 2026, while the company simultaneously pushes consumer-goods and overseas expansion built on its Hwalmyungsu and Hushidin brands.
2025 consolidated operating profit fell to about KRW 257 million from KRW 13.4 billion a year earlier, while owner net profit rose to about KRW 8.69 billion from KRW 5.56 billion.
Operating profit reached about KRW 11.2 billion in Q1 2026 and KRW 10.3 billion in Q2 2026, posting two consecutive quarters of triple-digit billion-won profit as cost efficiency took hold.
The company is expanding beyond its OTC-centered business into consumer goods and overseas channels through the Hwalmyungsu-branded carbonated drink 'Soda Hwal' and the global digestive drink 'K.O.D.'
The company is pursuing a Phase 1 clinical trial for the hypercholesterolemia treatment DW6025 to expand its prescription drug (ETC) portfolio.
Vietnamese distribution subsidiary Trung Son Pharma contributes meaningfully to revenue but has weighed on consolidated operating profit for several years.
Dongwha Pharmaceutical traces its roots to Hwalmyungsu, a digestive remedy launched in 1897, making it Korea's first modern pharmaceutical company, with over-the-counter (OTC) products forming the core of its revenue.
On a recent reporting basis, OTC lines such as Hwalmyungsu, Hushidin, Pancold, and Itchi account for roughly 60% of total sales, while prescription drugs (ETC), centered on improved and innovative formulations, make up about 20%.
Medisei, a medical device subsidiary acquired in 2020, produces orthopedic implants and other products as a new growth pillar, while Trung Son Pharma, a Vietnamese pharmacy chain acquired in 2023, is positioned to capture distribution growth tied to the expanding middle class.
In the competitive landscape, the company is grouped with Dong-A ST as an OTC leader, and both firms share a strategy of extending growth axes into beauty, healthcare, and medical devices.
More recently, the company has moved to extend the Hwalmyungsu and Hushidin brand equity beyond pharmaceuticals into consumer goods.
It launched the zero-sugar carbonated drink 'Soda Hwal,' containing digestive formula ingredients, and placed it in food-service channels including Lotteria and Gamachi Chicken, while the Hushidin brand is preparing an expansion into dermo-cosmetics.
Overseas, the company launched the global brand 'K.O.D (Korea Original Digestive)' based on Hwalmyungsu, securing placement at Olive Young in the United States and operating an Amazon brand storefront, in an effort to ease its domestic-heavy revenue structure.
Marketing campaigns featuring a K-pop idol group can also be seen as part of this overseas and consumer-goods expansion strategy.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩125B | ₩600M | 0.5% |
| 2025Q3 | ₩122B | ₩1.4B | 1.1% |
| 2025Q4 | ₩123.7B | -₩4B | −3.2% |
| 2026Q1 | ₩130.6B | ₩11.2B | 8.6% |
| 2026Q2 | ₩136.9B | ₩10.3B | 7.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩340.4B | ₩29.9B | ₩20.4B | 8.8% | 5.6% | 21.8% |
| 2023 | ₩361.1B | ₩18.8B | ₩27.4B | 5.2% | 7.4% | 38.8% |
| 2024 | ₩464.9B | ₩13.4B | ₩5.6B | 2.9% | 1.5% | 54.3% |
| 2025 | ₩496.4B | ₩300M | ₩8.7B | 0.1% | 2.3% | 60.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
2025 consolidated revenue rose to KRW 496.4 billion from KRW 464.9 billion a year earlier, but operating profit effectively evaporated to about KRW 257 million from KRW 13.4 billion.
The company attributed this to one-off costs incurred during a business restructuring process, while owner net profit nonetheless rose to about KRW 8.69 billion from KRW 5.56 billion, aided by improved financial asset valuation gains.
By quarter, operating profit was about KRW 614 million in Q2 2025 and KRW 1.37 billion in Q3 2025, before swinging to an operating loss of about KRW 4.0 billion in Q4 2025, a quarterly loss that explains much of the full-year weakness. The picture shifted markedly in 2026, however.
Q1 revenue reached KRW 130.6 billion (+3.9% year on year) with operating profit jumping to about KRW 11.2 billion, and owner net profit rebounding to about KRW 10.0 billion.
Q2 2026 continued the trend with revenue of KRW 136.9 billion and operating profit of about KRW 10.3 billion, marking two consecutive quarters of triple-digit-billion-won operating profit.
Cumulative owner net profit over the trailing four quarters (Q3 2025 through Q2 2026) reached about KRW 18.1 billion, already exceeding the full 2025 owner net profit of KRW 8.69 billion.
The 2026 improvement reflects a combination of simultaneous cuts in selling and R&D expenses alongside solid sales of core OTC products, suggesting the one-off cost burden from 2025 has eased.
Still, given operating profit declined for three straight years from KRW 29.9 billion in 2022 to KRW 18.8 billion in 2023, KRW 13.4 billion in 2024, and about KRW 257 million in 2025, it remains premature to conclude from two quarters of improvement in 2026 that the medium-term profitability trend has fully reversed.
Korea's OTC drug market is relatively sensitive to the economic cycle and carries comparatively high cost burdens, with industry observers repeatedly noting that low factory prices and high distribution margins make it difficult to convert sales growth into profitability.
Dong-A ST, grouped alongside Dongwha Pharm as an OTC leader, posted similar simultaneous top-line and bottom-line improvement in Q2 2026, with revenue up 10.9% year on year and operating profit up 18.1%.
The fact that both companies share a strategy of extending growth axes into beauty, healthcare, and medical devices suggests that diversification among traditional OTC pharmaceutical companies has become an industry-wide trend.
With innovative pharmaceutical company certification and drug pricing system reforms pending, whether companies with high OTC exposure can retain innovative-company status through re-certification is cited as a variable.
Southeast Asian pharmaceutical distribution markets such as Vietnam are seen as holding growth potential from an expanding middle class and rising health awareness, but this comes with upfront investment burdens tied to building local inventory and logistics infrastructure.
Compared with the broader Korean pharma-bio sector, where active technology licensing deals in innovative biologics such as antibody-drug conjugates (ADCs) continue, Dongwha Pharm occupies a distinct position by pursuing brand-asset-based consumer goods and overseas expansion together with ETC portfolio growth, rather than relying primarily on a new-drug pipeline.
The company plans to run a Phase 1 clinical trial for the hypercholesterolemia treatment DW6025 from September 2026 through August 2027, part of a strategy to ease its OTC-heavy structure and raise the ETC share over the medium term. Consumer-goods expansion is already translating into concrete distribution agreements.
The carbonated drink 'Soda Hwal' was placed in Lotteria outlets nationwide in July, and from October it is set to begin supply to roughly 900 Gamachi Chicken outlets, with joint marketing and combo-menu offerings also planned.
Overseas, the Hwalmyungsu-based global brand 'K.O.D' is progressing through a phased channel expansion plan, moving from domestic pharmacies and duty-free stores into U.S. mart and pharmacy chains, Olive Young, and an Amazon brand storefront.
The company itself has noted that because the launch starts in select U.S. regions rather than nationwide, a large near-term increase in the export share is unlikely, implying overseas revenue contribution will likely emerge gradually.
For the Hushidin brand's dermo-cosmetics expansion, a lineup plan starting with three products and growing to as many as six has been presented.
In its Q1 2026 earnings commentary the company stated a policy of expanding its medium-term growth base, and in Q2 it reiterated an intent to sustain stable growth through strengthening core brand competitiveness and broadening its product portfolio.
Dongwha Pharm's share price has moved within the price-to-earnings (PER) band it has traded in over recent years, and as operating profit has recovered on a quarterly basis entering 2026, the earnings base underlying that ratio has also shifted.
Its price-to-book ratio (PBR) trades below net asset value, placing it in a range typically described as a discount to shareholders' equity. On the dividend side, the company has maintained a cash dividend, though the dividend yield itself is generally classified as below the sector average.
Because operating profit nearly disappeared in full-year 2025, annual earnings-based ratios showed considerable volatility, making it necessary to interpret such ratios alongside the gap between annual results and more recent quarterly performance.
With the trailing four quarters now reflected, where the recent profit recovery sits relative to the multi-year trading band remains a point worth watching.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Operating profit registered in the triple-digit-billion-won range for two consecutive quarters in Q1 and Q2 2026, reflecting efficiency gains from simultaneous cuts in selling and R&D expenses.
This marks a reversal from the Q4 2025 operating loss, suggesting the one-off cost burden from business restructuring is easing. It is also notable that trailing-four-quarter owner net profit has already exceeded the full-year 2025 figure.
The company is expanding into carbonated drinks, dermo-cosmetics, and overseas digestive drinks by leveraging long-standing brands such as Hwalmyungsu and Hushidin. Placements at food-service chains like Gamachi Chicken and Lotteria, along with securing U.S.
Olive Young and Amazon channels, represent concrete progress in revenue diversification. This carries strategic significance as an attempt to ease the domestic-heavy revenue structure.
By advancing a Phase 1 trial for the hypercholesterolemia treatment DW6025, the company is concretizing a medium-term strategy to move away from an OTC-heavy revenue structure.
Developing an improved formulation of an already-approved drug can be viewed as a relatively lower-risk path compared with developing a wholly new drug. If the ETC share expansion succeeds, it carries potential to contribute to an improved profitability structure.
2025 consolidated operating profit collapsed more than 98% to about KRW 257 million from KRW 13.4 billion a year earlier, effectively disappearing.
Whether the one-off factors the company cited, such as business restructuring costs, will avoid recurring in 2026 remains something that needs to be confirmed over several more quarters.
Given operating profit declined for three straight years from 2022, it is premature to call two quarters of 2026 improvement a structural turnaround.
Vietnamese distribution subsidiary Trung Son Pharma contributes significantly to revenue but has repeatedly been cited as a drag on consolidated operating profit over several years.
Costs associated with building inventory and logistics systems during outlet expansion are identified as a factor delaying profitability improvement. The uncertain timing of when the overseas distribution subsidiary's profit and loss normalizes warrants continued monitoring.
A substantial portion of revenue still depends on economically sensitive OTC products, leaving the company exposed to both OTC cost-ratio pressure and economic slowdown effects simultaneously.
It will likely take more time before the ETC clinical program or new consumer-goods businesses meaningfully contribute to revenue and profit. While diversification is underway, the revenue mix transition is not yet complete.
As shown by the Q4 2025 operating loss followed by two consecutive quarters of sharp improvement in 2026, quarter-to-quarter earnings volatility is considerable.
Non-operating factors such as financial asset valuation gains and losses affect net profit, which can create a divergence between operating profit and net profit. The possibility of additional one-off costs related to business restructuring cannot be ruled out.
Both the K.O.D launch in the United States and the Trung Son Pharma operation in Vietnam require building local distribution and marketing infrastructure in advance, raising the possibility that revenue contribution lags initial investment.
The company itself has noted that U.S. sales are starting in select regions, making a large near-term rise in the export share unlikely. If overseas consumer response and channel expansion fall short of expectations, the investment payback period could lengthen.
With drug pricing system reforms and innovative pharmaceutical company re-certification pending, companies with a high OTC revenue mix are seen as potentially facing a less favorable position in the re-certification review. Changes in certification status can affect R&D-related benefits and external reputation.
The ETC clinical trial is also still at an early Phase 1 stage, and the possibility of development delays or discontinuation cannot be ruled out.
The statutory filing deadline for the Q3 2026 quarterly report, a point to check whether the operating profit improvement seen in Q1 and Q2 2026 continued into the third quarter.
The point at which 'Soda Hwal' supply to roughly 900 Gamachi Chicken outlets begins, allowing an initial read on the new consumer-goods business's sales performance.
The period during which the Phase 1 trial for hypercholesterolemia treatment DW6025 is conducted, warranting monitoring for any interim results or progress disclosures.
Innovative pharmaceutical company re-certification results are due, making it worth checking whether Dongwha Pharm, with its high OTC exposure, retains its existing status.
Continued monitoring is needed on the progress of K.O.D's U.S. sales channel expansion (Olive Young, Amazon, etc.) and whether Trung Son Pharma's profit and loss shows improvement.
Dongwha Pharm endured a sharp decline in full-year 2025 operating profit to near-zero, but Q1 and Q2 2026 showed a marked operating profit recovery driven by cost efficiency across two consecutive quarters.
On the business side, the company is diversifying into consumer goods and overseas markets—carbonated drinks, dermo-cosmetics, and a U.S. market entry—by leveraging long-standing brand equity in Hwalmyungsu and Hushidin, while also pursuing clinical development to expand its ETC portfolio.
However, factors such as profitability drag from subsidiaries like Trung Son Pharma in Vietnam, economic sensitivity stemming from an OTC-heavy revenue mix, and regulatory variables around drug pricing and certification remain areas requiring balanced scrutiny.
The fact that trailing four-quarter cumulative profit has already surpassed the full 2025 figure is a positive signal, but given three straight years of prior profit decline, whether the recent two-quarter improvement represents a structural shift will need confirmation through further quarterly results.
The new consumer-goods and overseas businesses remain at an early stage, and the timing and scale of their actual revenue and profit contribution will need ongoing verification through future disclosures.
Investment judgment should weigh the progress of this business diversification together with quarter-to-quarter earnings volatility, a decision best left to the individual reader.
Report written 2026-10-02 · Data as of 2026-10-01
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.